With increasing accesibility to artificial intelligence (AI) tools in daily life, patients can now obtain a greater depth of information about their condition, tailored to their individual needs. This issueā€™s cover story explores how using these AI applications will be vital in advancing medicine and healthcare, but human interaction might remain a vital part of patient care.

Also in this issue, we report on how Horizon EU funding could aid British biotech, and if a voucher system may incentivise antimicrobial drug discovery in Europe. Following several recent developments in the world of drugs for non-alcoholic steatohepatitis (NASH), we also have an article mapping the path forward for several investigational therapies.

Donā€™t miss the special thematic supplement replete with data and commentary on the potential for the pharma and healthcare sector in the metaverse. All this, with the latest news, analysis and data on the pharmaceutical and biotech industry.

Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile ā€“ free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.